Enhance Health is doing for liver and kidney disease what Hinge Health did for back pain: turning episodic, reactive care into continuous, proactive management.
Every 90 seconds, someone in the United States visits the emergency room for a condition that likely could have been caught weeks earlier, if only there had been a signal. For the tens of millions of Americans managing chronic liver and kidney disease, the current standard of care amounts to a handful of lab tests per year, a physician visit every few months, and a lot of waiting and hoping nothing goes wrong in between.
That gap between visits is where crises happen. It's where hepatic encephalopathy (a serious, often reversible decline in brain function caused by liver failure or cirrhosis, leading to toxins like ammonia building up in the brain) escalates silently, kidney function deteriorates without warning, and a patient ends up in the ICU for something that began as a subtle trend no one was watching.
Enhance Health, a VIC Tech portfolio company, was built to close that gap.
A proven playbook, a new arena
To understand Enhance's opportunity, consider what Hinge Health accomplished in musculoskeletal care. Before Hinge, back and joint pain was managed reactively: Pain flared, patients called their doctor, maybe saw a physical therapist. Hinge recognized that a digital platform combining wearable sensors, guided exercise, behavioral coaching, and longitudinal data could transform that episodic model into something continuous and measurable. The market rewarded that insight: Hinge Health went public in 2025 at a $4.5 billion valuation.
The chronic organ disease space (liver, kidney, and their downstream cardiovascular consequences) presents a structurally identical opportunity, with a market several times larger. Combined US spending on chronic kidney and liver disease exceeds $160 billion annually, driven largely by avoidable hospitalizations and late-stage interventions. The clinical problem is the same: Diseases that progress silently between visits, patients who can't measure what matters at home, and care teams flying blind.
Enhance Health is applying the same platform logic Hinge used in musculoskeletal care—proprietary diagnostics, AI-driven trend analysis, human coaching, and clinician integration—to an entirely unaddressed disease category.
The technology edge: measuring what was unmeasurable
The company's entry point is ammonia, a biomarker that offers an unusually early window into organ instability across liver disease, kidney disease, and rare genetic conditions called urea cycle disorders. Ammonia responds to deterioration before standard lab markers like creatinine or ALT even begin to shift, making it an ideal signal for trend-based, at-home monitoring. The problem has always been that ammonia is exceptionally difficult to test outside a clinical setting, requiring specialized blood handling and rapid processing.
Enhance has cracked that problem. The company's proprietary Breeze device uses a colorimetric breath sensor to detect ammonia levels non-invasively at home, either daily or weekly, without a needle. A companion urine ACR test and a finger-stick blood ammonia test round out the diagnostic menu, all assessed on the same platform device. The FDA has granted Breakthrough Device Designation for the breath ammonia system, validating both the unmet need and the novelty of the approach.
Clinical validation is well underway. Institutional Review Board-approved studies in both chronic kidney disease and urea cycle disorder patients have demonstrated the device's ability to discriminate disease severity and track treatment response.
A platform built to scale
Enhance's commercial model mirrors the subscription-based architecture that made Livongo and Omada Health high-value businesses: Recurring revenue from devices, consumables, app-based analytics, dedicated health coaching, and integrated telehealth. Patients receive continuous, personalized monitoring. Physicians get structured, longitudinal trend reports without added workflow burden. Payers and health systems see fewer avoidable ER visits, admissions, and readmissions: A compelling ROI case in a value-based care environment.
The go-to-market strategy is disciplined. Enhance enters through urea cycle disorders—a small, high-urgency rare disease population with acute unmet need and a fast regulatory path—before expanding into the vastly larger liver and kidney disease markets using the same technology platform. It's the same beachhead-to-platform strategy that Omada used to grow from a diabetes prevention program into a broad chronic condition business, ultimately reaching a $1.3 billion IPO valuation in 2025.
The team behind it
Enhance is led by Matt Leming, PhD, alongside a multidisciplinary team spanning biosensor engineering, liver disease medicine, medical device regulatory affairs, and health system commercialization. The company's Chief Medical Officer, Raj Sharma, MD, founded and scaled a multi-site Gastrointestinal Center of Excellence and brings deep clinical expertise in liver disease and chronic care management. The board includes advisors with experience at Siemens Healthineers, Kaiser Permanente, and Walmart Health, bringing commercial, clinical, and payer-side perspectives that few early-stage companies can access.
Enhance is backed and supported by VIC Tech venture studio, which provides operational infrastructure, regulatory support, and shared services that allow the team to execute with capital efficiency.
The opportunity, in plain terms
Chronic liver and kidney disease constitute one of the largest, most undermanaged disease categories in American healthcare, and one of the least disrupted by digital health innovation to date. Existing tools are fragmented, episodic, and single organ. No company has yet built the integrated monitoring and care platform this patient population needs.
Enhance Health has the proprietary technology, the clinical validation, the regulatory momentum, and the go-to-market clarity to be that company. The market analog is clear, the playbook has been proven, and the window to participate at the ground floor is open.
For more information, visit enhancehealthinc.com
About VIC Tech
Enhance Health is part of VIC Tech's portfolio, a venture studio focused on creating companies from innovative academic research. Enhance's Breeze is the third device from a VIC Tech portfolio company to receive Breakthrough Device Designation from the FDA, highlighting VIC’s consistent track record of advancing impactful health technologies toward clinical and commercial success.